Please use this identifier to cite or link to this item:
http://ir.mu.ac.ke:8080/jspui/handle/123456789/4847
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Heffron, Renee | - |
dc.contributor.author | Nelly, Mugo | - |
dc.contributor.author | Edwin, Were | - |
dc.contributor.author | Kiarie, James | - |
dc.contributor.author | Bukusi, Elizabeth A. | - |
dc.contributor.author | Mujugira, Andrew | - |
dc.contributor.author | Frenkel, Lisa | - |
dc.contributor.author | Donnell, Deborah | - |
dc.contributor.author | Ronald, Allan | - |
dc.contributor.author | Celum, Connie | - |
dc.contributor.author | Baeten, Jared M. | - |
dc.date.accessioned | 2021-07-14T09:35:27Z | - |
dc.date.available | 2021-07-14T09:35:27Z | - |
dc.date.issued | 2014 | - |
dc.identifier.uri | https://doi.org/10.1097/QAD.0000000000000493 | - |
dc.identifier.uri | http://ir.mu.ac.ke:8080/jspui/handle/123456789/4847 | - |
dc.description.abstract | Objective: To evaluate preexposure prophylaxis (PrEP) efficacy for HIV-1 prevention among women using depot medroxyprogesterone acetate (DMPA) for contraception and men whose HIV-1-infected partners use DMPA. Design: Secondary analysis of data from a randomized placebo-controlled trial of daily oral tenofovir and emtricitabine/tenofovir PrEP among heterosexual Kenyan and Ugandan HIV-1 serodiscordant couples. Methods: PrEP efficacy for HIV-1 prevention was compared among HIV-1-uninfected women using DMPA versus no hormonal contraception and among HIV-1 uninfected men whose HIV-1-infected female partners used DMPA versus no hormonal contraception. Results: Of 4747 HIV-1 serodiscordant couples, 901 HIV-1-uninfected women used DMPA at some point during follow-up, 1422 HIV-1-uninfected women used no hormonal contraception, 1568 HIV-1-uninfected men had female partners who used DMPA, and 2626 men had female partners who used no hormonal contraception. PrEP efficacy estimates for HIV-1 prevention, compared with placebo, were similar among women using DMPA and those using no hormonal contraception (64.7 and 75.5%, adjusted interaction P = 0.65). Similarly, for men whose female partners used DMPA, PrEP efficacy did not differ from men whose partners used no hormonal contraception (90.0 versus 81.7%, adjusted interaction P = 0.52). Conclusion: PrEP is efficacious for HIV-1 prevention among women using DMPA and men whose partners use DMPA, suggesting PrEP could mitigate the potential increased HIV-1 acquisition and transmission risks that have been associated with DMPA use. Women at risk for HIV-1 choosing DMPA could maintain this contraceptive method and add PrEP to achieve prevention of unintended pregnancy and HIV-1. | en_US |
dc.language.iso | en | en_US |
dc.publisher | NIH Public Access | en_US |
dc.subject | Contraceptive use | en_US |
dc.subject | HIV-1 prevention | en_US |
dc.title | PrEP is efficacious for HIV-1 prevention among women using DMPA for contraception | en_US |
dc.type | Article | en_US |
Appears in Collections: | School of Medicine |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.